Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Active Not Recruiting NCT06046040

TmPSMA-02 in mCRPC

Conditions: Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

Sex: Male

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE1

Enrollment: 30

Sponsor: University of Pennsylvania

Location: Abramson Cancer Center of the University of Pennsylvania Philadelphia Pennsylvania

Summary

This is a Phase I, open-label dose finding study to assess the safety, tolerability, manufacturing feasibility, and preliminary efficacy of TmPSMA-02 CAR T cells in patients with metastatic castrate-resistant prostate cancer (mCRPC). Up to 4 total dose levels will be evaluated using a 3+3 dose escalation design.

Eligibility Criteria

Inclusion Criteria: 1. Signed, written informed consent 2. Adult participants ≥ 18 years of age 3. Metastatic castrate-resistant prostate cancer (mCRPC) 4. Castrate levels of testosterone (\

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06046040). StuddyBuddy aggregates publicly available trial information.